Innovent Biologics appoints Dr. Stephen A. Sherwin as independent director

Innovent Biologics, Inc. announced the appointment of Dr. Stephen A. Sherwin, aged 76, as an independent non-executive director and a member of the board’s strategy committee, effective August 26, 2025. Dr. Sherwin, a clinical professor of medicine at the University of California, San Francisco, brings extensive experience in the life science industry, patient care, and medical oncology. His advisory work includes serving as an advisory partner at Third Rock Ventures since 2016 and directorships at Biogen since 2010 and Neurocrine Biosciences since 1999.

Dr. Sherwin's notable past roles include chairman and chief executive officer of Cell Genesys, co-founder and chairman of Abgenix, and co-founder and chairman of Ceregene. He also held various positions in clinical research at Genentech and served on the staff of the National Cancer Institute. Dr. Sherwin holds a bachelor's degree in biology from Yale University and a doctor of medicine degree from Harvard Medical School, received in 1970 and 1974, respectively.

He will serve a three-year term, subject to re-election, and will receive director’s fees of RMB400,000 per annum. The appointment aligns with Innovent's commitment to strong governance, with Dr. Sherwin meeting all independence criteria as stipulated by the listing rules. The board, as of the announcement date, includes Dr. De-Chao Michael Yu as chairman and executive director, and Dr. Sherwin as one of the independent non-executive directors.